Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options

被引：3

作者：

Schmidt, Andrew ^{[1
]}

Azad, Arun ^{[2
]}

Goh, Jeffrey ^{[3
,4
]}

Harris, Carole ^{[5
,6
]}

Joshua, Anthony M. ^{[7
]}

Weickhardt, Andrew ^{[8
]}

Krieger, Laurence ^{[9
]}

机构：

[1] Liz Plummer Canc Ctr, Cairns, Qld, Australia

[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[3] Royal Brisbane & Womens Hosp, Butterfield St, Herston, Qld, Australia

[4] Univ Queensland, St Lucia, Qld, Australia

[5] St George Hosp, Kogarah, NSW, Australia

[6] Sutherland Clin Sch UNSW, Kogarah, NSW, Australia

[7] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia

[8] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia

[9] Royal North Shore Hosp, Northern Canc Inst, Reserve Rd, St Leonards, NSW, Australia

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷

关键词：

immuno-oncology; renal cell carcinoma; VEGF tyrosine kinase inhibitors; INTERFERON-ALPHA; PREEXISTING AUTOIMMUNE; OPEN-LABEL; EVEROLIMUS; SUNITINIB; EFFICACY; SURVIVAL; CANCER; NEPHRECTOMY; LENVATINIB;

D O I：

10.1111/ajco.13289

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.

引用

页码：3 / 10

页数：8

共 50 条

[1] First-line therapy for metastatic renal cell carcinoma
Sawhney, Paramvir
Suyanto, Suyanto
Michael, Agnieszka
Pandha, Hardev
JOURNAL OF CLINICAL UROLOGY, 2024, 17 (02) : 190 - 200
[2] First-line treatment options in metastatic renal cell cancer
Kapoor, Anil
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (11-12): : S236 - S238
[3] First-line treatment of metastatic renal cell carcinoma
Bruchbacher, Andreas
Netsch, Christopher
Gross, Andreas J. J.
UROLOGIE, 2023, 62 (08): : 830 - 839
[4] Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
Escudier, Bernard
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1176 - 1178
[5] Axitinib as first-line therapy in metastatic renal cell carcinoma
Nozawa, Masahiro
Uemura, Hirotsugu
TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 555 - 557
[6] Tolerability of first-line therapy for metastatic renal cell carcinoma
Porta, Camillo
Szczylik, Cezary
CANCER TREATMENT REVIEWS, 2009, 35 (03) : 297 - 307
[7] New First-Line Systemic Treatment Options for Metastatic Esophageal Squamous Cell Carcinoma
Gibson, Michael K.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (5.5): : 579 - 582
[8] Optimising first-line treatment for metastatic renal cell carcinoma
de Velasco, Guillermo
LANCET, 2020, 395 (10219): : E7 - E7
[9] First-line Treatment Result Influence Second-line Regimen Selection in Targeted Therapy for Metastatic Renal Cell Carcinoma
Li, Jian-Ri
Yang, Cheng-Kuang
Wang, Shian-Shiang
Chen, Chuan-Shu
Chiu, Kun-Yuan
Cheng, Chen-Li
Yang, Chi-Rei
Ho, Hao-Chung
Ko, Jiunn-Liang
Ou, Yen-Chuan
ANTICANCER RESEARCH, 2014, 34 (10) : 5643 - 5647
[10] New therapy options for the treatment of metastatic renal cell carcinoma
Wolff, Ingmar
Burchardt, Martin
Kroeger, Nils
ONKOLOGE, 2019, 25 (06): : 523 - 528

← 1 2 3 4 5 →